Sun Pharma receives approval from DCGI to initiate clinical trial with Nafamostat in Covid-19 patients

29 May 2020 Evaluate

Sun Pharmaceutical Industries and its subsidiaries and/or associate companies have received approval from the Drugs Controller General of India (DCGI) to initiate a clinical trial with Nafamostat Mesilate in Covid-19 patients. Nafamostat is approved in Japan for improvement of acute symptoms of pancreatitis and treatment of Disseminated Intravascular Coagulation (DIC).

Globally, there are three clinical trials currently underway to test Nafamostat in Covid-19 patients. These trials are being led by the University of Tokyo Hospital, Japan; Gyeongsang National University Hospital (South Korea); and a collaborative trial by University Hospital, Padova, Italy, University of Zurich, Switzerland and Yokohoma City University, Japan (RACONA study).

Sun Pharmaceutical Industries is the world’s fourth largest specialty generic pharmaceutical company and India’s top pharmaceutical company.

 

Sun Pharma Inds. Share Price

1740.45 -54.65 (-3.04%)
18-Dec-2025 14:13 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1740.45
Dr. Reddys Lab 1274.55
Cipla 1495.00
Zydus Lifesciences 912.70
Lupin 2116.45
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×